BridgeBio Pharma, Inc. (BBIO) saw its stock price soar 5.16% in pre-market trading on Wednesday, as investors eagerly await the company's announcement of topline results from its crucial Phase 3 CALIBRATE study. The biotechnology firm is set to reveal the outcomes of the trial testing encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder affecting calcium levels in the body.

The anticipation surrounding these results has clearly sparked significant investor interest, driving the stock's noteworthy uptick. BridgeBio had previously announced that it would release the trial data before the market opens on Wednesday, October 28, 2025, followed by a conference call at 8:00 a.m. ET to discuss the findings in detail. This timing explains the pre-market movement as investors position themselves ahead of the potentially market-moving announcement.

The CALIBRATE study's results are crucial for BridgeBio's future prospects. Positive outcomes could potentially pave the way for a new treatment option for ADH1 patients and significantly strengthen the company's position in the rare disease therapeutics market. However, investors should note that the stock's performance may be subject to volatility depending on the actual data revealed. The biotech sector is known for sharp price movements in response to clinical trial results, and BridgeBio's stock is no exception to this trend.